MAPT and Alzheimer disease: Research indicates that modulation of the ECS, particularly via the CB1 and CB2 receptors, can exert neuroprotective effects in models of AD by mitigating β-amyloid toxicity, tau phosphorylation, and neuroinflammatory responses.